Arthneeti
NF

NGL Fine Chem Ltd

Q3 FY24Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q3 FY24 Results & Presentation Highlights: Revenue ₹87.95 Cr, PAT ₹10.03 Cr

Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.

Price₹2,895
Market cap₹1.7K Cr
P/E33.9
Updated24 Sept 2026
Read4 min read

Based on NGL Fine Chem Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). EBITDA (Q3FY24): ₹13.87 crores - Year-on-Year (YoY) growth: +41.32% - EBITDA Margin (Q3FY24): 15.77% (up 213 bps YoY) - Operating Margin: - Total Operating Expenses for Q3FY24: ₹74.08 crores - Operating margin not explicitly stated but can be inferred (~15.77% based on EBITDA margin and income) - Profit After Tax (PAT) (Q3FY24): ₹10.03 crores - YoY growth: +54.68% - PAT Margin (FY23 reported): 7% (Note: margin for Q3FY24 explicitly not stated) - Margin Outlook: - Management commentary notes marginal contract in margins this quarter due to slight raw material cost increase but expresses confidence in gradual sequential margin improvement going forward.

From NGL Fine Chem Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8).
  • Volume growth mentioned as a key driver of topline increase, despite competitive pricing pressures (Page 6).
  • Revenue from Veterinary API segment for FY23 was ₹258 crore, showing a 15% CAGR over FY19-FY23 (Page 11).
  • The presentation highlights robust volume growth leading to revenue improvement but notes some products have stable or slightly declining realizations (Page 6).
  • Outlook: Positive demand signals and recovery across markets, particularly exports (Bangladesh, Egypt), give confidence in gradual margin improvement and volume growth.

2 more points management made on revenue & sales performance

Profitability & Margins

See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Greenfield expansion at Tarapur through subsidiary Macrotech:
  • Completed expansion with additional intermediates capacity; commercial production started.
  • 50% capacity expansion planned to meet demand for new products.
  • Estimated total capex: ₹140 crore, funded through debt and internal accruals.
  • Civil construction ongoing; ₹45 crore invested till Q3FY24.
  • CAPEX project with phases:
  • Phase 1: Investment of ₹75 crore planned, ₹45 crore already invested.
  • Includes establishing utilities and operationalizing one clean room (API line).
  • Target completion by end of Q2FY25.
  • Phase 2: Involves activating remaining 5 clean rooms.
  • Planned operationalization by December 2025.
  • Additional ₹25 crore expected from internal accruals for both phases.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation provided does not explicitly mention or report any figures or details related to: - Order book - Order inflow - Pending orders None of the 16 pages in the presentation include information or metrics about order backlog or incoming orders. The focus is on financial performance, operational metrics, manufacturing capabilities, strategy, and management commentary, but there is no data on order book or order inflow reported in this document.

NGL Fine Chem Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q3 FY24)

    Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY24 investor presentation — and how it ranks against

  • Anuh Pharma Ltd (Q3 FY24)

    172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key investor presentation takeaways from Anuh Pharma Ltd's Q3 FY24 investor pres

  • Bharat Parenterals Ltd (Q3 FY24)

    Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key investor presentation takeaways from Bharat Parenterals Ltd's Q3 FY24 investor presentation — and how

  • Themis Medicare Ltd (Q3 FY24)

    82.51 Cr, down 7.06% year-on-year from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY24 investor presentation — and how it ranks again

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were NGL Fine Chem Ltd Q3 FY24 results?

Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). EBITDA (Q3FY24): ₹13.87 crores - Year-on-Year (YoY) growth: +41.32% - EBITDA Margin (Q3FY24): 15.77% (up 213 bps YoY) - Operating Margin: - Total Operating Expenses for Q3FY24: ₹74.08 crores - Operating margin not explicitly stated but can be inferred (~15.77% based on EBITDA margin and income) - Profit After Tax (PAT) (Q3FY24): ₹10.03 crores - YoY growth: +54.68% - PAT Margin (FY23 reported): 7% (Note: margin for Q3FY24 explicitly not stated) - Margin Outlook: - Management commentary notes marginal contract in margins this quarter due to slight raw material cost increase but expresses confidence in gradual sequential margin improvement going forward.

What is NGL Fine Chem Ltd share price analysis?

NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem Ltd planning capital expenditure?

Greenfield expansion at Tarapur through subsidiary Macrotech: - Completed expansion with additional intermediates capacity; commercial production started.

Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.